Company intelligence / Profile preview
Visterra
Waltham, Massachusetts, United Statesvisterrainc.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Visterra has a clinical-stage pipeline including VIS410 for influenza A which received FDA Fast Track Designation and entered Phase 2a trials in January 2017. They also have VIS705 in development for infectious diseases.
- Therapeutic areas
- Infectious DiseasesNephrology
- Modalities
- Antibody-based therapies
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Vir Biotechnology (research collaboration, exclusive license, and option agreement for infectious diseases)
Beyond the preview
Go deeper on Visterra.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Visterra.